# A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

> **NCT03459443** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 22 (actual)

## Conditions studied

- C3 Glomerulonephritis
- C3 Glomerulopathy
- Immune Complex Membranoproliferative Glomerulonephritis
- IC-MPGN
- Dense Deposit Disease

## Interventions

- **DRUG:** Danicopan

## Key facts

- **NCT ID:** NCT03459443
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-20
- **Primary completion:** 2021-03-29
- **Final completion:** 2021-03-29
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** The reason for terminating study early was inconclusive efficacy results. No safety findings were identified.
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03459443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03459443, "A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03459443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*